PMID- 28678552
OWN - NLM
STAT- MEDLINE
DCOM- 20170904
LR  - 20220317
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 16
IP  - 9
DP  - 2017 Sep
TI  - Acetylcholinesterase inhibitors for treating dementia symptoms - a safety 
      evaluation.
PG  - 1009-1019
LID - 10.1080/14740338.2017.1351540 [doi]
AB  - The prevalence of Alzheimer's disease (AD) continues to rise, while treatment 
      options for cognitive impairment are limited. Acetylcholinesterase inhibitors 
      (AChEIs) aim to provide symptomatic benefit for cognitive decline, however these 
      drugs are not without adverse events (AEs). The safety profile of each drug must 
      be taken carefully into consideration before being prescribed, as new dosages and 
      formulations have recently been approved. Areas covered: Donepezil, galantamine 
      and rivastigmine are the three AChEIs approved for the treatment of varying 
      stages of AD. Numerous clinical trials and post-marketing studies have evaluated 
      the safety of these medications. This article will review the safety, efficacy 
      and tolerability of these drugs in treating AD. Topics including 
      pharmacovigilance databases, concomitant drug interactions, prescribing cascades, 
      and treatment discontinuation are also covered. Expert opinion: AChEI use in 
      those with mild, moderate or severe AD provide modest improvements in cognition, 
      function and behavior. The pharmacological treatment of AD using AChEIs is 
      associated with generally mild AEs. Differences in drug formulations should be 
      taken into account when determining the most appropriate route of administration 
      for each individual. Furthermore, discontinuation of AChEIs must be carefully 
      monitored as it may be associated with worsening cognitive impairment.
FAU - Mohammad, Dana
AU  - Mohammad D
AD  - a Department of Pharmacology and Toxicology , University of Toronto , Toronto , 
      ON , Canada.
AD  - b Neuropsychopharmacology Research Group, Hurvitz Brain Sciences Program , 
      Sunnybrook Research Institute , Toronto , ON , Canada.
FAU - Chan, Parco
AU  - Chan P
AD  - a Department of Pharmacology and Toxicology , University of Toronto , Toronto , 
      ON , Canada.
AD  - b Neuropsychopharmacology Research Group, Hurvitz Brain Sciences Program , 
      Sunnybrook Research Institute , Toronto , ON , Canada.
FAU - Bradley, Janelle
AU  - Bradley J
AD  - b Neuropsychopharmacology Research Group, Hurvitz Brain Sciences Program , 
      Sunnybrook Research Institute , Toronto , ON , Canada.
FAU - Lanctot, Krista
AU  - Lanctot K
AD  - a Department of Pharmacology and Toxicology , University of Toronto , Toronto , 
      ON , Canada.
AD  - b Neuropsychopharmacology Research Group, Hurvitz Brain Sciences Program , 
      Sunnybrook Research Institute , Toronto , ON , Canada.
AD  - c Department of Psychiatry , University of Toronto , Toronto , ON , Canada.
FAU - Herrmann, Nathan
AU  - Herrmann N
AD  - b Neuropsychopharmacology Research Group, Hurvitz Brain Sciences Program , 
      Sunnybrook Research Institute , Toronto , ON , Canada.
AD  - c Department of Psychiatry , University of Toronto , Toronto , ON , Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170712
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Cholinesterase Inhibitors)
RN  - 0 (Indans)
RN  - 0 (Piperidines)
RN  - 0D3Q044KCA (Galantamine)
RN  - 8SSC91326P (Donepezil)
RN  - PKI06M3IW0 (Rivastigmine)
SB  - IM
MH  - Alzheimer Disease/*drug therapy/physiopathology
MH  - Cholinesterase Inhibitors/adverse effects/*therapeutic use
MH  - Cognition Disorders/drug therapy/physiopathology
MH  - Dementia/*drug therapy/physiopathology
MH  - Donepezil
MH  - Drug Interactions
MH  - Galantamine/adverse effects/therapeutic use
MH  - Humans
MH  - Indans/adverse effects/therapeutic use
MH  - Piperidines/adverse effects/therapeutic use
MH  - Rivastigmine/adverse effects/therapeutic use
MH  - Severity of Illness Index
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - acetylcholinesterase inhibitors
OT  - adverse events
OT  - donepezil
OT  - galantamine
OT  - pharmacovigilance
OT  - rivastigmine
OT  - safety
EDAT- 2017/07/06 06:00
MHDA- 2017/09/05 06:00
CRDT- 2017/07/06 06:00
PHST- 2017/07/06 06:00 [pubmed]
PHST- 2017/09/05 06:00 [medline]
PHST- 2017/07/06 06:00 [entrez]
AID - 10.1080/14740338.2017.1351540 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2017 Sep;16(9):1009-1019. doi: 
      10.1080/14740338.2017.1351540. Epub 2017 Jul 12.